In contrast, in vitro studies and analysis of clinical samples point mostly to a pro-tumorigenic role of DYRK1B and establish DYRK1B as a potential drug target in cancer therapy [4, 6, 9, 10]. The gene discussed is DYRK1B; the disease is cancer.